Generic Zomig Availability

See also: Generic Zomig-ZMT

Zomig is a brand name of zolmitriptan, approved by the FDA in the following formulation(s):

ZOMIG (zolmitriptan - spray; nasal)

  • Manufacturer: ASTRAZENECA
    Approval date: September 30, 2003
    Strength(s): 5MG/SPRAY [RLD]

ZOMIG (zolmitriptan - tablet; oral)

  • Manufacturer: IPR
    Approval date: November 25, 1997
    Strength(s): 2.5MG [AB], 5MG [RLD] [AB]

Has a generic version of Zomig been approved?

A generic version of Zomig has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zomig and have been approved by the FDA:

zolmitriptan tablet; oral

  • Manufacturer: APOTEX INC
    Approval date: May 14, 2013
    Strength(s): 2.5MG [AB], 5MG [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: May 14, 2013
    Strength(s): 2.5MG [AB], 5MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: May 14, 2013
    Strength(s): 2.5MG [AB], 5MG [AB]

Note: No generic formulation of the following product is available.

  • zolmitriptan - spray; nasal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Indolyl compounds for treating migraine
    Patent 5,466,699
    Issued: November 14, 1995
    Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
    Assignee(s): Burroughs Wellcome Co.
    ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
    Patent expiration dates:
    • November 14, 2012
    • November 14, 2012
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
    • May 14, 2013
      ✓ 
      Pediatric exclusivity
  • Therapeutic heterocyclic compounds
    Patent 5,863,935
    Issued: January 26, 1999
    Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
    Assignee(s): Zeneca Limited
    ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
    Patent expiration dates:
    • November 14, 2012
    • May 14, 2013
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical formulations containing zolmitriptan
    Patent 6,750,237
    Issued: June 15, 2004
    Inventor(s): Alan Roy; Dearn & Sarah Louise; Williamson & Simon John; Summers & Trevor John; Coomber
    Assignee(s): AstraZeneca AB
    A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
    Patent expiration dates:
    • November 28, 2020
      ✓ 
      Drug product
    • May 28, 2021
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical formulations containing zolmitriptan
    Patent 7,220,767
    Issued: May 22, 2007
    Inventor(s): Dearn; Alan Roy & Williamson; Sarah Louise & Summers; John Simon & Coomber; Trevor John
    Assignee(s): AstraZeneca AB
    A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
    Patent expiration dates:
    • November 28, 2020
      ✓ 
      Drug product
    • May 28, 2021
      ✓ 
      Pediatric exclusivity

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web2)